Cyanotic heart defect medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 17: | Line 17: | ||
*Get rid of extra fluids | *Get rid of extra fluids | ||
*Help the heart pump harder | *Help the heart pump harder | ||
*Treat abnormal heartbeats or rhythms | *Treat abnormal heartbeats or rhythms | ||
* In infants with severe polycythemia (>70 percent), an isovolumetric partial exchange transfusion should be performed with saline to reduce the hematocrit | |||
* Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established. | |||
==References== | ==References== | ||
Revision as of 19:52, 18 October 2012
|
Cyanotic heart defect Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cyanotic heart defect medical therapy On the Web |
|
American Roentgen Ray Society Images of Cyanotic heart defect medical therapy |
|
Risk calculators and risk factors for Cyanotic heart defect medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editor(s)-In-Chief: Keri Shafer, M.D. [2], Atif Mohammad, M.D.
Overview
Medical Therapy
Pharmacotherapy
Acute Pharmacotherapies
Infants that remain in the hospital may receive medicines to:
- Get rid of extra fluids
- Help the heart pump harder
- Treat abnormal heartbeats or rhythms
- In infants with severe polycythemia (>70 percent), an isovolumetric partial exchange transfusion should be performed with saline to reduce the hematocrit
- Prostaglandin E1 (alprostadil) — Administered in infants with clinical suspicion of ductal-dependent congenital heart defect until a definitive diagnosis or treatment is established.